Division of Hematology and Oncology, Chi Mei Medical Center, Tainan, Taiwan
Yin-Hsun Feng , Wu-Chou Su , Do-Youn Oh , Lin Shen , Kyu-Pyo Kim , Xiufeng Liu , Huimin Liao , Min Qing , Jiaqi Qian , Spyros Triantos , Hussein Sweiti , Joon Oh Park
Background: Pts with CCA progressing after first-line therapy have limited treatment options. We report an updated analysis of the ongoing LUC2001 open-label, multicenter, phase 2a study (NCT02699606) investigating the efficacy and safety of erdafitinib in Asian pts with advanced CCA and FGFR alterations who progressed after ≥1 prior systemic treatment. Methods: Eligible adults (aged ≥18 years) received erdafitinib 8 mg once daily (QD) with pharmacodynamically guided up-titration to 9 mg QD. The primary endpoint was objective response rate (ORR; RECIST 1.1); secondary endpoints included best overall response (BOR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Survival estimates were determined by the Kaplan–Meier method. Results: Of 232 patients with CCA who underwent molecular screening, 39 (16.8%) had FGFR alterations (21 [9.1%] fusions and 19 [8.2%] mutations). Overall, 22 (9.5%) eligible pts (median age, 52 [range, 29–69] years) were enrolled and received treatment. Median follow-up was 22.4 (range, 2.3–47.0) months; median treatment duration was 6.2 (range, 1.5–35.6) months. All 22 pts received ≥1 line of prior systemic therapy and 12 (55.0%) pts had ≥2 prior lines of therapy. The ORR was 40.9% (95% CI, 20.7%–63.6%) and median time to response was 1.8 (range, 1.5–5.6) months. Median DOR was 7.3 (95% CI, 3.7–17.5) months, median PFS was 5.6 (95% CI, 3.6–12.7) months, and median OS was 40.2 (95% CI: 9.9–not estimable) months (Table). Responses were observed in 8/14 pts with FGFR fusions and 1/8 pts with FGFR mutations and in pts who received 1 or ≥2 prior lines of therapy. All 22 pts had ≥1 treatment-emergent adverse event (TEAE), the most common being dry mouth (15/22 [68.2%]) and stomatitis (14/22 [63.6%]). Grade ≥3 TEAEs occurred in 15/22 (68.2%) pts (11/22 [50.0%] were treatment related), of which the most common were stomatitis (3/22 [13.6%]) and alanine aminotransferase (ALT) increased (3/22 [13.6%]); 11/22 (50.0%) pts had ≥1 serious TEAE (1/22 [4.5%] pts had a serious treatment-related TEAE). A TEAE leading to death occurred in 1 patient (sepsis; not treatment-related). Conclusions: Asian pts with advanced CCA and FGFR alterations treated with erdafitinib had durable efficacy and a manageable safety profile, supporting the earlier findings of erdafitinib benefit in this population. Clinical trial information: NCT02699606.
Variable | Total (N=22) |
---|---|
ORR (CR+PR), n (%)[95% CI]a | 9 (40.9) [20.7–63.6] |
DCR (CR+PR+SD), n (%)[95% CI]a | 18 (81.8) [59.7–94.8] |
BOR, n (%) | |
CR | 1 (4.5) |
PR | 8 (36.4) |
SD | 9 (40.9) |
PD | 4 (18.2) |
Median PFS (95% CI), months | 5.6 (3.6–12.7) |
Median OS (95% CI), months | 40.2 (9.9–not estimable) |
aCR/PR confirmed by repeat assessments ≥4 weeks from initial observation. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Shubham Pant
2019 ASCO Annual Meeting
First Author: Joon Oh Park
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Junji Furuse
2023 ASCO Annual Meeting
First Author: Shubham Pant